Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)



BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing
Rule 5635(c)(4)

SAN RAFAEL, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today announced that on April 15, 2013, the compensation
committee of BioMarin's board of directors approved the grant to 27 employees
of stock options to purchase 32,500 shares of common stock in the aggregate
and the grant to 25 of the 27 employees of 8,280 restricted stock units in the
aggregate. The stock options were granted pursuant to the BioMarin
Pharmaceutical Inc. 2012 Inducement Plan, approved by the compensation
committee of BioMarin's board of directors on May 8, 2012, and as inducements
material to the new employees entering into employment with BioMarin in
accordance with NASDAQ Listing Rule 5635(c)(4).

BioMarin granted to each of the 27 employees an option to purchase shares of
BioMarin's common stock with an exercise price equal to $63.21, the closing
price per share of BioMarin's common stock as reported by NASDAQ on April 15,
2013, the date of grant. Each of the options is an incentive stock option and
will vest 6/48ths on the six month anniversary of the grant date and 1/48th
per month thereafter for the 42 immediately following months, assuming in each
case the employee remains continuously employed by BioMarin. In addition, the
restricted stock units granted to 25 of the 27 employees will vest in equal
installments annually over four years, assuming the employee remains
continuously employed by BioMarin. BioMarin is providing this information in
accordance with NASDAQ Listing Rule 5635(c)(4).

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis
I (MPS I), a product which BioMarin developed through a 50/50 joint venture
with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for
phenylketonuria (PKU), developed in partnership with Merck Serono, a division
of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has
been approved by the European Commission for the treatment of Lambert Eaton
Myasthenic Syndrome (LEMS). Product candidates include BMN-110
(N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which
successfully completed Phase III clinical development for the treatment of MPS
IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is
currently in Phase II clinical development for the treatment of PKU, BMN-701,
a novel fusion protein of insulin-like growth factor 2 and acid alpha
glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development
for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase
(PARP) inhibitor, which is currently in Phase I/II clinical development for
the treatment of genetically-defined cancers, and BMN-111, a modified
C-natriuretic peptide, which is currently in Phase I clinical development for
the treatment of achondroplasia. For additional information, please visit
www.BMRN.com. Information on BioMarin's website is not incorporated by
reference into this press release.

Forward Looking Statements

This press release contains certain forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995 regarding,
among other things, statements relating to plans, objectives and future
events. BioMarin intends such forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are based on
the current expectations of the management of BioMarin as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause the actual results
to be materially different from those indicated by such forward-looking
statements. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements include,
among other, market risks. These and other risks are described in greater
detail in BioMarin's filings with the Securities and Exchange Commission
(SEC), including its Annual Report on Form 10-K for the year ended December
31, 2012. Given these uncertainties, you should not place undue reliance on
these forward-looking statements. BioMarin assumes no obligation to update its
forward-looking statements, except as required by law.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of
BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

CONTACT: Investors:
         Eugenia Shen
         BioMarin Pharmaceutical Inc.
         (415) 506-6570
        
         Media:
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement